Attenuation of amyotrophic lateral sclerosis via stem cell and extracellular vesicle therapy: An updated review
Neuroprotection · 2023-12 · 1 (2) · 130-138
DOI: 10.1002/nep3.26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuroprotection, online erschienen am 20.11.2023. Verfasst von Gavin Lockard und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of South Florida Morsani College of Medicine, Tampa, FL, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS.
Abstract (Originalsprache)
Amyotrophic lateral sclerosis (ALS) is a rapidly fatal neurological disease characterized by upper and lower motor neuron degeneration. Though typically idiopathic, familial forms of ALS are commonly composed of a superoxide dismutase 1 (SOD1) mutation. Basic science frequently utilizes SOD1 models in vitro and in vivo to replicate ALS conditions. Therapies are sparse; those that exist in the market extend life minimally, thus driving the demand for research to identify novel therapeutics. Transplantation of stem cells is a promising approach for many diseases and has shown efficacy in SOD1 models and clinical trials. The underlying mechanism for stem cell therapy presents an exciting venue for research investigations. Most notably, the paracrine actions of stem cell‐derived extracellular vesicles (EVs) have been suggested as a potent mitigating factor. This literature review focuses on the most recent preclinical research investigating cell‐free methods for treating ALS. Various avenues are being explored, differing on the EV contents (protein, microRNA, etc.) and on the cell target (astrocyte, endothelial cell, motor neuron‐like cells, etc.), and both molecular and behavioral outcomes are being examined. Unfortunately, EVs may also play a role in propagating ALS pathology. Nonetheless, the overarching goal remains clear: to identify efficient cell‐free techniques to attenuate the deadly consequences of ALS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of South Florida Morsani College of Medicine, Tampa, FL, USA.
- Department of Neurosurgery and Brain Repair, Center of Excellence for Aging and Brain Repair, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
Förderung
- NINDS NIH HHS
Zitieren
APA
Lockard, G., Gordon, J., Schimmel, S., Sayed, B. E., Monsour, M., Garbuzova-Davis, S., & Borlongan, C. V. (2023). Attenuation of amyotrophic lateral sclerosis via stem cell and extracellular vesicle therapy: An updated review. Neuroprotection, 1(2), 130-138. https://doi.org/10.1002/nep3.26
Vancouver
Lockard G, Gordon J, Schimmel S, Sayed BE, Monsour M, Garbuzova-Davis S, et al. Attenuation of amyotrophic lateral sclerosis via stem cell and extracellular vesicle therapy: An updated review. Neuroprotection. 2023;1(2):130-138. doi:10.1002/nep3.26
BibTeX
@article{Lockard2023,
author = {Lockard, Gavin and Gordon, Jonah and Schimmel, Samantha and Sayed, Bassel El and Monsour, Molly and Garbuzova-Davis, Svitlana and Borlongan, Cesar V},
title = {Attenuation of amyotrophic lateral sclerosis via stem cell and extracellular vesicle therapy: An updated review},
journal = {Neuroprotection},
year = {2023},
volume = {1},
number = {2},
pages = {130--138},
doi = {10.1002/nep3.26}
}
EUVIMED